Key result
Heart failure management pairs acute symptom relief with chronic disease-modifying therapies including sacubitril/valsartan.
Why the study?
Heart failure secondary to left ventricular systolic dysfunction is prevalent with ischemic heart disease as the most common cause, and management strategies continue to evolve.
This review outlines the standard of care and recent advances, such as sacubitril/valsartan, in the management of acute and chronic heart failure.
Outlines current HF standards; leaves open targeted acute therapies for prospective trials.
Heart failure secondary to left ventricular systolic dysfunction is a prevalent condition across Europe with ischemic heart disease the most common etiology. Acute heart failure is a medical emergency and management comprises diuretics and vasodilators. Several alternative intravenous treatments have been trialed in recent years but no mortality benefit has been found with these agents. For chronic heart failure there are several well‐characterized disease‐modifying treatments available which include beta blockers, ACE inhibitors, mineralocorticoid antagonists, and device therapy. Sacubitril/valsartan is a novel therapy that has recently been demonstrated to have additional prognostic benefit. Answer questions and earn CME: https://wileyhealthlearning.com/Activity2/5222693/Activity.aspx
No takes yet. Share an insight, caveat, or question.
Brown et al. (2017) conducted a review in Heart failure secondary to left ventricular systolic dysfunction. Heart failure treatments (diuretics, vasodilators, beta blockers, ACE inhibitors, sacubitril/valsartan) was evaluated. Current management of acute heart failure comprises diuretics and vasodilators, while chronic heart failure is managed with disease-modifying treatments including sacubitril/valsartan.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: